Press Release

Printer Friendly VersionView printer-friendly version << Back

Two Poster Presentations on Oral Peptides by Protagonist Therapeutics Accepted for the Upcoming 2015 Advances in IBD – Crohn’s & Colitis Foundation’s Clinical & Research Conference

Milpitas, CA (October 20, 2015): Two poster presentations on oral peptides by Protagonist Therapeutics accepted for the upcoming 2015 Advances in IBD – Crohn's & Colitis Foundation’s Clinical & Research Conference, and their abstracts will be published in the February 2016 issue of Inflammatory Bowel Disease.

Abstract titles:

“PTG-100, an oral peptide antagonist of integrin α4β7 that alters trafficking of gut homing T cells in preclinical animal models”

“Discovery of novel oral peptide antagonists of IL-23 receptor that are efficacious in a rat model of IBD”

About Protagonist Therapeutics

Protagonist Therapeutics is a U.S.-incorporated biotechnology company engaged in the discovery and development of orally stable peptides as targeted therapy for inflammatory bowel diseases (IBD) and other gastrointestinal diseases and disorders. The company has an innovative and proprietary technology platform that enables it to develop potent and orally stable peptides against protein-protein interaction (PPI) targets that are otherwise undruggable by small molecules and therefore have historically been approached largely by injectable antibodies. Oral peptides may lead to a superior and safer choice for IBD patients, physicians, and payers by virtue of their better convenience and compliance, and potentially enhanced safety and efficacy in comparison to other therapeutic options. The company is nearing the completion of IND-enabling studies of an alpha-4-beta-7 integrin-specific oral peptide antagonist PTG-100, and has several other assets including the oral IL-23 receptor antagonist in different stages of research and pre-clinical development.

Protagonist is headquartered in Milpitas, California USA and is a spin-out from the University of Queensland’s Institute of Molecular Biosciences (IMB). The company has its pre-clinical and clinical operations in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit

# # #

For Media:

Joan Kureczka
Kureczka/Martin Associates
Tel +1.415.821.2413
Mobile +1.415.690.0210